COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre

Size: px
Start display at page:

Download "COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre"

Transcription

1 COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre

2 Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial Disclosure Company Grants / Research Support Speakers Honorarium Consulting Fees Patents Other None Astrazeneca, BMS, Takeda Boeringher Ingelheim, Abbott Eli Lilly, Amgen, Mylan, Janssen Forest Laboratories, J&J, Merck, Novartis, Pfizer, Servier, Sanofi None None None

3 Mitigating Potential Bias Only published data will be presented in this program and recommendations will be based on published Guidelines

4 Learning Objectives: By the end of this workshop you will be able to: 1. Make appropriate diagnosis 2. Understand appropriate testing 3. Be able to incorporate guidelines into the management of your patients 4. Understand the role of new therapies for the management of your patients

5 Percent Change in Age-Adjusted Death Rates, U.S., (Proportion of 1965 Rate)

6

7

8 Air trapping

9 Mr. CO 76 year old man Short of breath Had Negative Cardiac workup Smoker 40 pk years Coughs most days some sputum Meds: ARB, Statin, ASA, Vitamins

10 Global Strategy for Diagnosis, Management and Prevention of COPD Diagnosis of COPD SYMPTOMS shortness of breath chronic cough sputum EXPOSURE TO RISK FACTORS tobacco occupation indoor/outdoor pollution SPIROMETRY: Required to establish diagnosis 2013 Global Initiative for Chronic Obstructive Lung Disease

11 11

12 Focus on Vital Capacity (VC) 12

13 Spirometry: Normal Trace Showing FEV 1 and FVC 5 FVC Volume, liters FEV 1 = 4L FVC = 5L FEV 1 /FVC = Time, sec 2013 Global Initiative for Chronic Obstructive Lung Disease

14 Spirometry: Mr. CO 5 Normal 4 Volume, liters FEV 1 = 1.8L FVC = 3.2L FEV 1 /FVC = 0.56 Obstructive < Time, seconds 2013 Global Initiative for Chronic Obstructive Lung Disease

15 Mr. CO Walking can t keep up with his wife

16 Assessing Disability in COPD

17 Mr. CO FEV1 is 70% predicted

18 Global Strategy for Diagnosis, Management and Prevention of COPD Classification of Severity of Airflow Limitation in COPD* based on FEV 1 GOLD 1: Mild GOLD 2: Moderate GOLD 3: Severe GOLD 4: Very Severe FEV 1 > 80% predicted 50% < FEV 1 < 80% predicted 30% < FEV 1 < 50% predicted FEV 1 < 30% predicted *Based on Post-Bronchodilator FEV Global Initiative for Chronic Obstructive Lung Disease

19 Global Strategy for Diagnosis, Management and Prevention of COPD Classification of Severity of Airflow Limitation in COPD* based on FEV 1 GOLD 1: Mild GOLD 2: Moderate GOLD 3: Severe GOLD 4: Very Severe FEV 1 > 80% predicted 50% < FEV 1 < 80% predicted 30% < FEV 1 < 50% predicted FEV 1 < 30% predicted *Based on Post-Bronchodilator FEV Global Initiative for Chronic Obstructive Lung Disease

20 Global Strategy for Diagnosis, Management and Prevention of COPD Classification of Severity of Airflow Limitation in COPD* based on FEV 1 GOLD 1: Mild Mr. CO FEV1 = 70% FEV 1 > 80% predicted GOLD 2: Moderate 50% < FEV 1 < 80% predicted GOLD 3: Severe GOLD 4: Very Severe 30% < FEV 1 < 50% predicted FEV 1 < 30% predicted *Based on Post-Bronchodilator FEV Global Initiative for Chronic Obstructive Lung Disease

21 Mr. CO 5 years he had 3 exacerbations

22 What is the impact of exacerbations on mortality? 50% of COPD patients are dead within 4 years of being admitted for first time with COPD 1 A= No Exacerbations B= 1-2 Exacerbations C= > 3 Exacerbations 1.Suissa S, Dell Aniello S, Ernst P. Thorax. doi: /thorax.jnl , 2.Soler-Cataluna JJ, et al. Thorax. 2005;60:

23 Suissa S et al. Thorax 2012;67:

24 Suissa S et al. Thorax 2012;67:

25 Daily rates of death (per per day) in the 90-day period after onset of severe chronic obstructive pulmonary disease exacerbation. Suissa S et al. Thorax 2012;67: Copyright BMJ Publishing Group Ltd & British Thoracic Society. All rights reserved.

26 LAMA vs Placebo for Exacerbation 80 * Probability of exacerbation (%) Hazard ratio: 0.86 CI: *p<0.001 No. at risk Month Tiotropium Placebo Tashkin DP, et al. N Engl J Med. 2008;359:

27 LAMA vs LAMA + LABA Formoterol + Tiotropium Change from baseline in trough FEV 1 (ml) Trough FEV 1 : Change from baseline * n=108 n=118 n=127 n=121 n=106 n=121 n=121 n=129 Week 4 Week 8 Week 12 Last visit * * Mean change in symptom score Total COPD Symptom Score * AM * PM AM/PM average * Formoterol (12 µg b.i.d.) + tiotropium (18 µg o.d.) Tiotropium (18 µg o.d.) *p<0.05; p<0.001 vs. tiotropium; sum of scores for dyspnea (0 = none to 4 = severe), wheezing, cough, and chest ghtness (0 = none to 3 = very uncomfortable). Tashkin DP, et al.: COPD 2009; 6(1):17 25.

28 TORCH ICS vs LABA vs Combo Calverley PMA et al. N Engl J Med 2007;356:

29 LAMA vs LAMA + ICS + LABA % reduction in rate of severe exacerbation Ratio: 0.38 (95% CI: ) P < BUD/FORM + TIO PBO + TIO Exacerbations/patient Poisson regression Days since randomisation BUD/FORM=budesonide/formoterol (320/9 μg bid); PBO = placebo; TIO = tiotropium (18 μg od) Welte T, et al. Am J Respir Crit Care Med. 2009;180:

30 Global Strategy for Diagnosis, Management and Prevention of COPD Combined Assessment of COPD GOLD FEV1 4 3 ICS (C) + LABA or LAMA ICS + LABA (D) and/or LAMA >2 <50% Predicted Exacerbations 2 1 SAMA prn (A) or SABA prn LABA (B) or LAMA 1 0 mmrc 0-1 CAT < Global Initiative for Chronic Obstructive Lung Disease Symptoms mmrc > 2 CAT > 10

31 Treatment of Stable COPD 2017 Global Initiative for Chronic Obstructive Lung Disease

32 Bronchodilator LAMA or LABA 2 Bronchodilators LAMA + LABA Bronchodilators + ICS LAMA + LABA + ICS

33 Pharmacotherapy Indicated for COPD in Canada BRONCHODILATORS SHORT ACTING BETA 2 AGONISTS LONG ACTING BETA 2 AGONISTS SHORT ACTING ANTICHOLINE RGICS LONG ACTING ANTICHOLINERGICS Umeclidinium (bromide) INCRUISE Ellipta 62.5 mcg CORTICOSTERIODS/LONG ACTING BETA 2 AGONISTS Budesonide/Formoterol (fumarate) ANTICHOLINERGICS AND LONG ACTING BETA 2 AGONISTS Ipratropium (bromide)/ Salbutamol (sulfate) Glycopyrronium (bromide)/ Indacaterol (maleate) Umeclidinium (bromide)/ Vilanterol (trifenatate) Tiotropium (bromide)/ Olodaterol (hydrochloride) Aclidinium (bromide)/ Formoterol (fumarate) COMBIVENT Respimat 20/100 mcg Chart not representative of all approved COPD medications Canada. INSPIOLTO Respimat 2.5/2.5 mcg accessed June 24, 2015 DUAKLIR Genuair 400/ 12 mcg

34 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 34

35 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 35

36 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 36

37 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 37

38 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 38

39 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) LABA SABA Device Long-acting beta 2 agonist Efficacy Safety Short-acting beta 2 agonist Formoterol Salmeterol Indacaterol Vilanterol Olodaterol Salbutamol Terbutaline Oxeze (Turbuhaler) Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Striverdi (Respimat) Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 39

40

41 1 Adapted from : Newman SP, et al. Lung Deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicine: Comparison of Respimat with conventional metereddose inhalers with and without spacer devices. Chest1998;113:

42 DPI (Diskus) Slide the lever away from you as far as it will go Breathe out until lungs are empty Place the mouthpiece in mouth and close lips firmly around it Breathe in as fast & as hard as you can until lungs are full Hold breath for 10s Breathe out Adapted from asthmameds.ca

43 43

44 44

45 45

46 Respimat

47 Turbuhaler

48 Devices Green & Go Red & Done Feedback on successful inhalation Audible click when patient is inhaling sufficiently Control window turns red when inhalation is complete Tudorza Genuair Product Monograph, 2013

49 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) LABA SABA Device Long-acting beta 2 agonist Efficacy Safety Short-acting beta 2 agonist Formoterol Salmeterol Indacaterol Vilanterol Olodaterol Salbutamol Terbutaline Oxeze (Turbuhaler) Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Striverdi (Respimat) Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 49

50 LAS39: Change from baseline FEV 1 by timepoint over 24 hours at Day 1 *p<0.05 aclidinium vs tiotropium This study alone does not constitute a head-to-head study to support comparative claims of aclidinium vs tiotropium. Beier et al. COPD 2013

51 Aclidinium reduces COPD exacerbation (any severity) rates (24 weeks): ATTAIN 1.6 Placebo Aclidinium 400 µg BID 1.39 COPD exacerbations (/pt/year) % p< % p< Healthcare Resource Utilization criteria EXACT criteria Reproduced with permission Jones et al. CHEST 2012

52 Canadian RWE A retrospective observational propensity-matched cohort study Healthcare utilisation in the first year after initiating ICS/LABA therapy Courses of oral steroids/year (0.72, 1.00) ED visits/year (0.58, 0.97) Hospital admissions/year (0.47, 0.81) Addition of a tiotropium prescription/year (0.57, 0.89) In Canada, 5255 COPD patients were treated with an ICS/LABA before matching 3969 (76%) patients in this cohort used FLU/SAL 36% had exacerbations pre-index More bud/form vs. flu/sal pats. had a first ICS/LABA initiated by a specialist (8% more) Antibiotics were not evaluated as a definition of exacerbations Patients were tracked for 1 year Blais L et al. Clin Ther 2010; 32 (7): 1320 These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph.

53 COPD Exacerbations BUD/FOR (n=2734) or FLU/SAL (n=2734) Rate ratio (95% CI) All exacerbations ** NNT = (0.69, 0.79) Oral steroids ** 0.74 (0.68, 0.81) Antibiotics ** BUD/FOR 0.70 (0.66, 0.75) Hospitalisations ** NNT = 16 SAL/FLU 0.71 (0.65, 0.78) Emergency visits * 0.79 (0.71, 0.89) Event rate per 100 patient years Adjusted yearly rates of healthcare utilisation events were compared using Poisson regression analysis. **P<0.0001; *P= for difference. CI, confidence intervals; BUD/FOR, budesonide/formoterol; FLU/SAL, fluticasone/salmeterol These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph. Larsson et al. J Intern Med 2013; DOI: /joim.12067

54 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) LABA Device Long-acting beta 2 agonist Efficacy Formoterol Salmeterol Indacaterol Vilanterol Oxeze (Turbuhaler) Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) SABA Safety Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 54

55 Pneumonia Risk in COPD Patients (Stratified by ICS Type) Meta analysis of ICS use (studies 1 3 yr duration) Corticosteroid Type Fluticasone (16 studies) Budesonide (7 studies) Mometasone (1 study) Risk Ratio HR (95%CI) 1.67 ( )* 1.19 ( ) [ns] 2.00 ( ) [ns] Corticosteroid Safer Corticosteroid Harmful *statistically significant increase with fluticasone p< [ns] = no statistically significant increase in risk detected The elderly and those with more severe disease and lower FEV1s are at the highest risk of pneumonia. Singh S, Loke YJ. Curr Opin Pulm Med. 2010; 16:

56 Cumulative Pneumonia Rate vs Time Post Index Cumulative pneumonia rate per 100 patients Fluticasone/salmeterol group Any pneumonia Hospitalised pneumonia Budesonide/formoterol group Any pneumonia Hospitalised pneumonia All pneumonias RR 1.73 (1,57; 1.90) P<0.001 NNT 23 Hospitalised pneumonias RR 1.74 (1,56; 1.94) P<0.001 NNT Years Adjusted yearly pneumonia event rates compared using Poisson regression analysis. Janson et al. BMJ 2013;346:f3306 DOI: /bmj.f3306 These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph.

57 An Immunosuppressant / Infection hypothesis Fluticasone /salmeterol ASL Mucosa/Lung tissue ASL = Airway surface liquid Budesonide Budesonide/GCS-receptor Bacteria Fluticasone Fluticasone/GCS-receptor These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph. 1. Wedzicha JA et al. AJRCCM Calverley et al. Chest 2011;139: Patterson C et al Respiratory Research 2012,13:40 4. Ek A et al Allergy (1999). 54: Miller-Larsson et al. AJRCCM (2000). 162: Johnsson M et al Allergy (1995) 50:s Dalby C, et al. Respir Res (2009); 10:104

58 Dissolution Time in Airway Fluid Water solubility (μg/ml) Dissolution time (human BAL fluid in vitro) Flunisolide 140 <2 min Triamcinolone 21 n.d. acetonide Budesonide 16 6 min Beclomethasone 17-propionate Fluticasone 17-propionate Beclomethasone dipropionate 16 n.d >8h 0.13 >5h Högger and Rohdewald, Rev Contemp Pharm 1998 n.d.= no data These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph.

59 Dissolution Time in Airway Fluid Water solubility (μg/ml) Dissolution time (human BAL fluid in vitro) Flunisolide 140 <2 min Triamcinolone 21 n.d. acetonide Budesonide 16 6 min Beclomethasone 17-propionate Fluticasone 17-propionate Beclomethasone dipropionate 16 n.d >8h 0.13 >5h Högger and Rohdewald, Rev Contemp Pharm 1998 n.d.= no data These slides have been supplied, on request, by AstraZeneca Scientific Affairs. For complete therapeutic and safety information please consult the SYMBICORT Product Monograph.

60 Safety: Hydrolysis of LAMAs Gavaldà et al Two major acid and alcohol metabolites are inactive Sentellas et al, 2010 Alberti et al, 2010

61 ICS + LABA Advair (Diskus) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 61

62 ICS + LABA Symbicort (Turbuhaler) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 62

63 ICS + LABA Breo (Ellipta) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 63

64 LAMA + LABA Anoro (Ellipta) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 64

65 LAMA + LABA Ultibro (Breezhaler) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 65

66 LAMA + LABA Stiolto Respimat Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Vilanterol Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Olodaterol Striverdi (Respimat) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 66

67 LAMA + LABA Duaklir (Genuair) Abbreviation Full name Examples Brand ICS Inhaled corticosteroid Budesonide Fluticasone Proprionate Fluticasone Furoate Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) LAMA LAAC Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Formoterol Oxeze (Turbuhaler) LABA Long-acting beta 2 agonist Salmeterol Indacaterol Serevent (Diskus) Onbrez (Breezhaler) Vilanterol (Ellipta) SABA Short-acting beta 2 agonist Salbutamol Terbutaline Ventolin (Diskus) Bricanyl (Turbuhaler) SAMA Short-acting antimuscarinic Ipratropium Atrovent 67

68 Treatments for COPD Abbreviation Full name Examples Brand (Device) ICS LAMA LAAC LABA SABA SAMA Inhaled corticosteroid Long-acting anticholinergic (also known as long-acting muscarinic antagonist) Long-acting beta 2 agonist Short-acting beta 2 agonist Short-acting antimuscarinic Budesonide Fluticasone Proprionate Fluticasone Furoate Tiotropium Glycopyrronium Aclidinium Bromide Umeclidinium Device Efficacy Formoterol Salmeterol Indacaterol Vilanterol Safety Salbutamol Terbutaline Pulmicort (Turbuhaler) Flovent (Diskus) (Ellipta) Spiriva (Respimat) Seebri (Breezhaler) Tudorza (Genuair) Incruse (Ellipta) Oxeze (Turbuhaler) Serevent (Diskus) Onbrez (Breezhaler) (Ellipta) Ventolin (Diskus) Ipratropium Atrovent Bricanyl (Turbuhaler) 68

69 COPD Risk & Smoking Cessation 1,5,7 Never smoked or not susceptible to smoke FEV 1 (% of value at age 25) Smoked regularly and susceptible to effects of smoke Disability Death Stopped smoking at 45 (mild COPD) Stopped smoking at 65 (severe COPD) Age (years) Fletcher C et al. Br Med J. 1977;1:

70 Peter COPD Lin MD CCFP Maze Director Primary Care Initiatives Canadian Heart Research Centre Keep COPD in DDx Tools for Assessing Risk Medications: Bronchodilators vs ICS Step up: Single then dual then triple Rx Decide based on: Device, Efficacy, Safety Avoid Exacerbations

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program

More information

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018 Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize

More information

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or

More information

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic

More information

THE COPD PRESCRIBING TOOL

THE COPD PRESCRIBING TOOL THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their

More information

Wirral COPD Prescribing Guidelines

Wirral COPD Prescribing Guidelines Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed

More information

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial

More information

Three better than 1 or 2?

Three better than 1 or 2? Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma

More information

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies

More information

Test Your Inhaler Knowledge

Test Your Inhaler Knowledge A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary

More information

Three s Company - The role of triple therapy in chronic obstructive pulmonary

Three s Company - The role of triple therapy in chronic obstructive pulmonary Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov

More information

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD)

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)

More information

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed

More information

2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017

2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain

More information

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed

More information

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed

More information

If you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team

If you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:

More information

HSN S FORMULARY ALTERNATIVES FOR STABLE COPD. Which drug comes with which device?

HSN S FORMULARY ALTERNATIVES FOR STABLE COPD. Which drug comes with which device? HSN S FORMULARY ALTERNATIVES FOR STABLE COPD Which drug comes with which device? Long-Acting Bronchodilators LAMAs LABAs LONG ACTING MUSCARINIC ANTAGONISTS Blocks acetylcholine-mediated bronchoconstriction

More information

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

COPD 2016 What to do with all these New Inhalers?

COPD 2016 What to do with all these New Inhalers? COPD 2016 What to do with all these New Inhalers? Planning committee Content Experts Clinical reviewers Paul Hernandez MDCM FRCPC, Department of Respirology, QEII Health Sciences Centre, Associate Professor,

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex

More information

INHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop

INHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers

More information

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18 Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

Common Drug Review Pharmacoeconomic Review Report

Common Drug Review Pharmacoeconomic Review Report Common Drug Review Pharmacoeconomic Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indication Listing request Dosage form(s) Manufacturer Indicated for long-term, once daily maintenance

More information

Respiratory Inhalers. Identification Guide Version 3

Respiratory Inhalers. Identification Guide Version 3 Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical

More information

CHARM Guidelines for the diagnosis and

CHARM Guidelines for the diagnosis and \ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,

More information

Select Inhaled Respiratory Agents

Select Inhaled Respiratory Agents Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

GMMMG COPD Formulary Inhaler Options October 2017

GMMMG COPD Formulary Inhaler Options October 2017 BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram

More information

STRIVERDI RESPIMAT (olodaterol hcl) aerosol

STRIVERDI RESPIMAT (olodaterol hcl) aerosol STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Address Comorbidities

Address Comorbidities Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure

More information

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint

More information

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint

More information

Co. Durham & Darlington Respiratory Network COPD Treatment Guide

Co. Durham & Darlington Respiratory Network COPD Treatment Guide Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination

More information

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung

More information

Pharmacotherapy for COPD

Pharmacotherapy for COPD 10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR

More information

April 10 th, Bond Street, Toronto ON, M5B 1W8

April 10 th, Bond Street, Toronto ON, M5B 1W8 Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond

More information

He is still Short of Breath Is there any new puffer? Saidul Ansary

He is still Short of Breath Is there any new puffer? Saidul Ansary He is still Short of Breath Is there any new puffer? Saidul Ansary Mr S C 66 yr. old retired Engineer for pre op elective assessment I am fine but Anaesthetist said I need to see you. I am little bit SOB,

More information

COPD Inhaled Therapy Prescribing Guidance

COPD Inhaled Therapy Prescribing Guidance COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR

More information

Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)

Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version

More information

COPD Inhaled Therapy Prescribing Guidance

COPD Inhaled Therapy Prescribing Guidance COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Prescribing guidelines: Management of COPD in Primary Care

Prescribing guidelines: Management of COPD in Primary Care Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Take My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care

Take My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care Take My Breath Away: Update Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care Objectives 1. Recognize clinical signs and symptoms associated with chronic bronchitis and emphysema. 2. Describe

More information

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting

More information

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,

More information

Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section.

Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section. Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE

More information

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease

More information

Michelle Zeidler, MD, MS

Michelle Zeidler, MD, MS 7/1/18 Chronic Obstructive Pulmonary Disease: Optimizing Outpatient Care & Reducing Exacerbations Michelle Zeidler, MD, MS Professor of Medicine, Pulmonary, Critical Care Medicine & Sleep Medicine, VA

More information

What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018

What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018 What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018 No disclosures Disclosures objectives How to diagnose & Assess severity Treatment: Pharmacologic Non-Pharmacologic Maintenance

More information

COPD Prescribing Guidelines

COPD Prescribing Guidelines Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning

More information

COPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center

COPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center COPD 2018 GOLD 2017 Report Global Initiative for Chronic Obstructive Lung D isease COPYRIGHTED MATERIAL- DO NOT COPY OR DISTRIBUTE GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC

More information

COPD: Current Medical Therapy

COPD: Current Medical Therapy COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for

More information

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved. Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects

More information

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to: Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict

More information

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October

More information

Algorithm for the use of inhaled therapies in COPD

Algorithm for the use of inhaled therapies in COPD Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

These lung function tests involve you being seated and breathing into specialist equipment (like that shown below), via a filter and a mouthpiece.

These lung function tests involve you being seated and breathing into specialist equipment (like that shown below), via a filter and a mouthpiece. Lung Function Tests This leaflet only gives you general information about the lung function (breathing) tests. However, it does not replace the need for the personal advice from the health care professional.

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Long Term Care Formulary RS -29

Long Term Care Formulary RS -29 RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)

More information

Algorithm for the use of inhaled therapies in COPD Version 2 May 2017

Algorithm for the use of inhaled therapies in COPD Version 2 May 2017 Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments

More information

Medical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017

Medical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017 Medical Directive Pre and Post Bronchodilator Spirometry Testing and Treatment Initiation Assigned Number: Activation Date: April 24, 2013 Review due by: December 1, 2019 23 Approval Signature & Date Medical

More information

Drug Effectiveness Review Project Summary Report

Drug Effectiveness Review Project Summary Report Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed

More information

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking

More information

12:00 Autonomic Drugs 12:00. Autonomic Drugs

12:00 Autonomic Drugs 12:00. Autonomic Drugs Autonomic Drugs Autonomic Drugs 12:04 PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS PILOCARPINE HCL 5 MG ORAL TABLET 00002216345 SALAGEN 1.4298 PYRIDOSTIGMINE BROMIDE 60 MG ORAL TABLET 00000869961 MESTINON

More information

Shared System of Care COPD/Heart Failure

Shared System of Care COPD/Heart Failure Shared System of Care COPD/Heart Failure Learning Session 2 www.pspbc.ca Agenda Introduction (35) Sharing Experiences(10) Medication (60, 40 didactic and 20 discussion) MOA Breakout Break (15) PSM Support

More information

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

COPD: A Renewed Focus. Disclosures

COPD: A Renewed Focus. Disclosures COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE: CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Asthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives

Asthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives Asthma & COPD Medication Review Anna Meador, PharmD, BCACP Assistant Professor/ Pharmacy Director McWhorter School of Pharmacy/ Christ Health Center Amber Hutchison, PharmD, BCPS Assistant Clinical Professor

More information

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled

More information

Balanced information for better care. Helping patients with COPD breathe easier

Balanced information for better care. Helping patients with COPD breathe easier Balanced information for better care Helping patients with COPD breathe easier COPD is the third-leading cause of death in the U.S., following cancer and heart disease 1 FIGURE 1. Women now have a higher

More information

ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12

ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate

More information

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules

More information

FDCs for CO PD: From Famine to a Feast of Therapeutic Choices

FDCs for CO PD: From Famine to a Feast of Therapeutic Choices FDCs for CO PD: From Famine to a Feast of Therapeutic Choices LAURA RUNKEL, PhD Associate Director, CNS, AutoImmune/Inflammation, Ophthalmology Historically, there have been few therapies developed for

More information

reslizumab (Cinqair )

reslizumab (Cinqair ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Improving Outcomes in COPD

Improving Outcomes in COPD Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea

More information

Management of COPD Updates and Evidence

Management of COPD Updates and Evidence Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Changing Landscapes in COPD New Zealand Respiratory Conference

Changing Landscapes in COPD New Zealand Respiratory Conference Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview

More information

Asthma/COPD Update with Inhaler Workshop

Asthma/COPD Update with Inhaler Workshop Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial

More information

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%

More information

Dr Stephen Child. Chief Medical Officer Southern Cross Health Society Auckland

Dr Stephen Child. Chief Medical Officer Southern Cross Health Society Auckland Dr Stephen Child Chief Medical Officer Southern Cross Health Society Auckland 7:00-7:55 GlaxoSmithKline Breakfast Session - Hot Topics in Airways Disease: COPD and Asthma Hot Topics in Airways Disease:

More information

Respiratory Health. Asthma and COPD

Respiratory Health. Asthma and COPD Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory

More information

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe

More information

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and

More information

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives. Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

GOLD 2017: cosa c è di nuovo

GOLD 2017: cosa c è di nuovo GOLD 2017: cosa c è di nuovo Antonio Spanevello Università degli Studi dell Insubria, Varese Dipartimento di Medicina e Chirurgia Istituti Clinici Scientifici Maugeri, IRCCS, Tradate Dipartimento di Medicina

More information

11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures

11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical

More information

FASENRA (benralizumab)

FASENRA (benralizumab) FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong

More information